Evidence map›Paper›PMID 26167667›Full record

ArticleNucleosides, nucleotides & nucleic acids2015

Design, Synthesis, and Evaluation of Anti-HBV Activity of Hybrid Molecules of Entecavir and Adefovir: Exomethylene Acycloguanine Nucleosides and Their Monophosphate Derivatives.

Shuhei Imoto, Satoru Kohgo, Ryoh Tokuda, Hiroki Kumamoto, Manabu Aoki, Masayuki Amano, Nobuyo Kuwata-Higashi, Hiroaki Mitsuya, Kazuhiro Haraguchi

Abstract read
In one paragraph

Article in Nucleosides, nucleotides & nucleic acids, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuhei Imotoa Faculty of Pharmaceutical Sciences, Sojo University , Nishi-ku , Kumamoto , Japan.
Satoru Kohgo
Ryoh Tokuda
Hiroki Kumamoto
Manabu Aoki
Masayuki Amano
Nobuyo Kuwata-Higashi
Hiroaki Mitsuya
Kazuhiro Haraguchi

Funding

Development of Novel Agents Active against Hepatitis B VirusZIABC011486 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MITSUYA, HIROAKI · 2013 to 2025
$3.0M
Intramural NIH HHS ZIA BC011486
6 · The paper itself

Abstract

Exomethylene acycloguanine nucleosides 4, 6 and its monophosphate derivatives 5, 7, and 8 have been synthesized. Mitsunobu-type coupling of 2-N-acetyl-6-O-diphenylcarbamoylguanine (11) with primary alcohols proceeded regioselectively to furnish the desired N(9)-substituted products in moderate yield. Evaluation of 4-8 for anti-HBV activity in HepG2 cells revealed that the phosphonate derivative 8 was found to exhibit moderated activity (EC50 value of 0.29 μM), but cytotoxicity (CC50 value of 39 μM) against the host cells was also observed.

Indexed as

Drug DesignAdenineAntiviral AgentsGuanineHepatitis B virusHep G2 CellsHumansIn Vitro TechniquesOrganophosphonatesadefovirAdenineAntiviral AgentsentecavirGuanineOrganophosphonatesacyclonucleosideadefoviranti-HBV activityentecavirhybridNucleosidenucleoside phosphonatepro-drug

Identifiers

PMID26167667
PMCPMC7712530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.